Neuromuscular disorders in systemic malignancy

Current Opinion in Neurology

Volumn 10, Issue 5, 1997, Pages 371-375

  Stübgen, Joerg Patrick ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; HEPARIN; NAVELBINE; PACLITAXEL; SURAMIN; VINCRISTINE; WARFARIN;

ANTICOAGULANT THERAPY; AUTOIMMUNITY; AXILLA; BRACHIAL PLEXUS; BRACHIAL PLEXUS INJURY; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; HUMAN; HUMORAL IMMUNITY; IRRADIATION; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MOTOR NEURON DISEASE; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PARANEOPLASTIC SYNDROME; PERIPHERAL NERVE; POLYMERASE CHAIN REACTION; POLYRADICULITIS; REVIEW; SENSORY NEUROPATHY; SPINE;

EID: 0030825776     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199710000-00003     Document Type: Review

References (36)

1. Stübgen J-P: Neuromuscular disorders in systemic malignancy and its treatment. Muscle Nerve 1995, 18:636-648.
2. Hughes R, Sharrack B, Rubens R: Carcinoma and the peripheral nervous system. J Neurol 1996, 243:371-376.
3. Rosenfeld MH, Posner JB: Paraneoplastic motor neuron disease. Adv Neurol 1991, 56:445-459.
4. Dalman J, Graus F, Rosenblum MK, Posner JB: Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy: a clinical study of 71 patients. Medicine 1992, 7:59-72.
5. Verma A, Berger JR, Snodgrass S, Petito C: Motor neuron disease: a paraneoplastic process associated with anti-Hu antibody and small cell lung carcinoma. Ann Neurol 1996, 40:112-116. A case report of pure motor neuron syndrome as variant of paraneoplastic encephalomyelitis is provided.
6. Dalman J, Posner JB: Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994, 44:2241-2246.
7. Carter GT, Fritz RC: Pancreatic adenocarcinoma presenting as a monomelic motor neuronopathy. Muscle Nerve 1997, 20:103-105.
8. Pourmand R, Maybury BG: AAEM case report #31: paraneoplastic sensory neuronopathy. Muscle Nerve 1996, 19:1517-1522. A concise summary of sensory neuro(no)pathies is provided.
9. Jean WC, Dalman J, Ho A, Posner JB: Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994, 44:140-147.
10. Byrne T, Mason WP, Posner JB, Dalman J: Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997, 62:276-278.
11. Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993, 341:21-22.
12. Briellmann RS, Sturzenegger M, Gerber HA, Schaffner T, Hess CW: Autoantibody-associated sensory neuronopathy and intestinal pseudo-obstruction without detectable neoplasia. Eur Neurol 1996, 36:369-373.
13. Graus F, Ramon R: Paraneoplastic neuropathies. Eur Neurol 1993, 33:279-286.
14. Bowen J, Gregory R, Squier M, Donaghy M: The post-irradiation lower motor neuron syndrome: neuronopathy or radiculopathy? Brain 1996, 119:1429-1439. This is a detailed investigation of post-irradiation radiculopathy, which has not been well researched before.
15. Ku A, Lachman E, Tunkel R, Nagler W: Upper limb reflex sympathetic dystrophy associated with occult malignancy. Arch Phys Med Rehabil 1996, 77:726-728.
16. Olsen NK, Pfeiffer P, Johannsen L, Schroder H, Rose C: Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993, 26:43-49.
17. Yarnold JR, Price R, Steel GG: Non-surgical management of early breast cancer in the United Kingdom: radiotherapy dose fraction practices. Clin Oncol 1995, 7:223-226.
18. Thyagarajan D, Cascino T, Harms G: Magnetic resonance imaging in brachial plexopathy of cancer. Neurology 1995, 45:421-427.
19. Glantz MJ, Burger PC, Friedman AH, Radthe RA, Massey EW, Schold SC: Treatment of radiation induced nervous system injury with heparin and warfarin. Neurology 1994, 44:2020-2027.
20. Gemignani F, Marchesi G, DiGiovanni G, Salih S, Quaini F, Nobile-Orazio E: Low-grade non-Hodgkin B-cell lymphoma presenting as sensory neuropathy. Eur Neurol 1996, 36:138-141. The differential diagnosis of sensory neuropathies increases.
21. Levin KH, Lutz G: Angiotropic large-cell lymphoma with peripheral nerve and skeletal muscle involvement: early diagnosis and treatment. Neurology 1996, 47:1009-1011.
22. Créange A, Théodorou I, Sabourin J-C, Vital C, Farcet J-P, Gherardi RK: Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. J Neurol Sci 1996, 137:35-41. Polymerase chain reaction was used for the first time to analyse inflammatory cells in lymphoproliferative diseases; the distinction between neoplastic and paraneoplastic damage becomes blurred.
23. Antoine JC, Mosnier GF, Lapras J, Convers P, Absi L, Laurent B, Michel D: Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996, 60:188-190.
24. Bird SG, Brown MJ, Shy ME, Scherer SS: Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 1996, 46:822-824. Melanocytes and Schwann cells are derived from the neural crest and potentially share surface antigens.
25. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF: Phase I trial of the murine monoclonal anti-GDs antibody 14G2a in metastatic melanoma. Cancer Res 1992, 52:4342-4347.
26. Fuller GN, Spies JM, Pollard JD, McLeod JG: Demyelinating neuropathy triggered by melanoma immunotherapy. Neurology 1994, 44:2404-2405.
27. Freilich RJ, Balmaceda C, Seidman A, Rubin M, DeAngelis LM: Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996, 47:115-118. A distal axonopathy caused by taxoids must be included in the differential diagnosis of proximal weakness in cancer patients.
28. Van den Bent MJ, Van Raaij-Van den Aarssen VJM, Doorn PAV, Sillevis-Smith PAE: Progression of paclitaxel-induced neuropathy following discontinuation of treatment. Muscle Nerve 1997, 20:750-752.
29. New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ: Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996, 46:108-111.
30. Hilkens PHE, Verweij J, Stoter G, Vecht ChJ, van Putten WLJ, van den Bent: Peripheral neurotoxicity induced by docetaxel. Neurology 1996, 46:104-108.
31. Pace A, Bove L, Nistico C, Ranuzzi M, Innocenti P, Pietrangeli A, Terzoli E, Jandolo B: Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996, 61:409-111.
32. Chaudry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR: A prospective study of suramin-induced peripheral neuropathy. Brain 1996, 119:2039-2052. This is a detailed study of suramin neuropathy, a disorder not well researched in the past.
33. Cavaletti G, Bogliun G, Vittorio C, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G: Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 1997, 15:199-206.
34. Barajon I, Bersani M, Quartu M, del Fiacco M, Cavaletti G, Holst JJ, Tredici G: Neuropeptldes and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 1996, 138:93-104.
35. Weintraub M, Adde MA, Venzon DG, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT: Severe atypical neuropathy associated with administration of hemopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935-940. CSFs are an independent risk factor for development of vincristine neuropathy.
36. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM: Steroid myopathy in cancer patients. Neurology 1997, 48:1234-1238. Steroid-induced weakness is common in neuro-oncologic patients, but is reversible; no new insight is provided into the mechanism of the myopathy.